News
BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...
An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...
BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...
4d
InvestorsHub on MSNPfizer and BioNTech Receive Positive EMA Backing for Updated COVID VaccinePfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...
A global biotech is axing more of its Greater Washington workforce, eliminating nearly 100 positions across multiple waves of ...
BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out why I rate BNTX stock a hold for now.
New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
Pfizer and partner BioNTech announced they have submitted a request on Friday to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine candidate.
BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 202 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results